BR0208468A - Camsilato de amlodipina e processo para sua preparação - Google Patents

Camsilato de amlodipina e processo para sua preparação

Info

Publication number
BR0208468A
BR0208468A BR0208468-6A BR0208468A BR0208468A BR 0208468 A BR0208468 A BR 0208468A BR 0208468 A BR0208468 A BR 0208468A BR 0208468 A BR0208468 A BR 0208468A
Authority
BR
Brazil
Prior art keywords
preparation
amlodipine
amlodipine camsylate
camsylate
camsilate
Prior art date
Application number
BR0208468-6A
Other languages
English (en)
Other versions
BR0208468B1 (pt
BRPI0208468B8 (pt
Inventor
Young Ho Moon
Nam Du Kim
Kyung Ik Lee
Gwan Sun Lee
Jong Soo Woo
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36792806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0208468(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of BR0208468A publication Critical patent/BR0208468A/pt
Publication of BR0208468B1 publication Critical patent/BR0208468B1/pt
Publication of BRPI0208468B8 publication Critical patent/BRPI0208468B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

"CAMSILATO DE AMLODIPINA E PROCESSO PARA SUA PREPARAçãO". O camsilato de amlodipina da presente invenção e um sal cristalino de amlodipina adequado para formulação farmacêutica, que é preparado com o uso de ácido canforsulfónico menos tóxico para atender às propriedades farmacêuticas requeridas para o tratamento de doenças cardiovasculares.
BRPI0208468A 2001-03-29 2002-03-28 camsilato de amlodipina e processo para sua preparação BRPI0208468B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2001-0016514A KR100452491B1 (ko) 2001-03-29 2001-03-29 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법
PCT/KR2002/000543 WO2002079158A1 (en) 2001-03-29 2002-03-28 Novel amlodipine camsylate and method for preparing thereof

Publications (3)

Publication Number Publication Date
BR0208468A true BR0208468A (pt) 2004-03-02
BR0208468B1 BR0208468B1 (pt) 2017-10-31
BRPI0208468B8 BRPI0208468B8 (pt) 2021-05-25

Family

ID=36792806

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0208468A BRPI0208468B8 (pt) 2001-03-29 2002-03-28 camsilato de amlodipina e processo para sua preparação

Country Status (22)

Country Link
US (1) US6936625B2 (pt)
EP (1) EP1373207B1 (pt)
JP (1) JP4188088B2 (pt)
KR (1) KR100452491B1 (pt)
CN (1) CN1238342C (pt)
AT (1) ATE498612T1 (pt)
AU (1) AU2002243069B2 (pt)
BR (1) BRPI0208468B8 (pt)
CA (1) CA2441613C (pt)
CZ (1) CZ304489B6 (pt)
DE (1) DE60239193D1 (pt)
DK (1) DK1373207T3 (pt)
ES (1) ES2360787T3 (pt)
HK (1) HK1066545A1 (pt)
HU (1) HU227919B1 (pt)
IL (2) IL158082A0 (pt)
MX (1) MXPA03008675A (pt)
NZ (1) NZ528362A (pt)
PL (1) PL207535B1 (pt)
PT (1) PT1373207E (pt)
RU (1) RU2241701C1 (pt)
WO (1) WO2002079158A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070135488A1 (en) * 2002-04-13 2007-06-14 Chung You S Amlodipine nicotinate and process for the preparation thereof
KR100496436B1 (ko) * 2002-07-30 2005-06-20 씨제이 주식회사 암로디핀의 유기산염
KR100538641B1 (ko) 2002-07-30 2005-12-22 씨제이 주식회사 암로디핀의 유기산염
KR100462304B1 (ko) * 2002-07-30 2004-12-17 씨제이 주식회사 암로디핀의 유기산염
KR20040011751A (ko) * 2002-07-30 2004-02-11 씨제이 주식회사 암로디핀의 유기산염
JP2007528349A (ja) * 2003-01-27 2007-10-11 ハンミ ファーム． シーオー．， エルティーディー． 高い安定性を有する無定形アムロジピンカムシレート、その製造方法及びこれを含む経口投与用組成物
WO2005042485A1 (en) * 2003-10-30 2005-05-12 Sk Chemicals, Co., Ltd. Acid added salts of amlodipine
KR100841409B1 (ko) * 2003-12-16 2008-06-25 에스케이케미칼주식회사 암로디핀 겐티세이트 염과 이의 제조방법
KR100632470B1 (ko) * 2005-02-25 2006-10-12 민연식 결정성 시부트라민 캄실레이트염과 이의 제조방법
KR100913791B1 (ko) * 2006-07-21 2009-08-26 한미약품 주식회사 (ｓ)-(-)-암로디핀 캠실레이트 또는 이의 수화물 및 이를함유하는 약학적 조성물
KR100830003B1 (ko) 2006-10-31 2008-05-15 씨제이제일제당 (주) 결정성 ｓ-(-)-암로디핀 아디핀산 염 무수물 및 이의 제조방법
KR100843401B1 (ko) * 2006-12-04 2008-07-04 씨제이제일제당 (주) 결정성 ｓ-(-)-암로디핀 캠실레이트 무수물 및 이의제조방법
KR100840069B1 (ko) * 2007-01-23 2008-06-20 씨제이제일제당 (주) 결정성 ｓ-(-)-암로디핀 오로테이트 무수물 및 이의제조방법
KR100799821B1 (ko) * 2007-02-05 2008-01-31 동화약품공업주식회사 신규한 이마티닙 캠실레이트 및 그의 제조방법
CA2749903C (en) * 2009-01-23 2016-09-06 Jae Hyun Park Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
DK3150610T3 (da) 2010-02-12 2019-11-04 Pfizer Salte og polymorfer af 8-fluor-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-on
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
CN102266333B (zh) * 2011-08-19 2012-08-29 海南锦瑞制药股份有限公司 一种含有左旋氨氯地平和阿托伐他汀钙的全新药用组合物及其制备方法
US9650336B2 (en) 2011-10-10 2017-05-16 Astrazeneca Ab Mono-fluoro beta-secretase inhibitors
US10548882B2 (en) * 2012-06-21 2020-02-04 Astrazeneca Ab Camsylate salt
KR101910901B1 (ko) 2013-11-29 2018-10-24 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제
KR101914930B1 (ko) 2015-03-31 2018-11-05 한미약품 주식회사 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합 제제

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK161312C (da) * 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
GB8608335D0 (en) * 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US6057344A (en) * 1991-11-26 2000-05-02 Sepracor, Inc. Methods for treating hypertension, and angina using optically pure (-) amlodipine
KR100188391B1 (ko) 1993-08-27 1999-06-01 류정열 전기자동차의 충전중 표시 장치
KR100374405B1 (ko) 2000-06-21 2003-03-04 한국유나이티드제약 주식회사 암로디핀 베실레이트의 제조방법
CA2433181C (en) * 2000-12-29 2005-11-22 Pfizer Limited Amlodipine hemifumarate

Also Published As

Publication number Publication date
PL362667A1 (en) 2004-11-02
PT1373207E (pt) 2011-03-01
BR0208468B1 (pt) 2017-10-31
IL158082A0 (en) 2004-03-28
HK1066545A1 (en) 2005-03-24
EP1373207A4 (en) 2009-01-21
JP4188088B2 (ja) 2008-11-26
AU2002243069B2 (en) 2004-10-14
BRPI0208468B8 (pt) 2021-05-25
PL207535B1 (pl) 2010-12-31
HUP0303639A2 (hu) 2004-03-01
RU2241701C1 (ru) 2004-12-10
US20040116478A1 (en) 2004-06-17
CA2441613C (en) 2009-02-03
DK1373207T3 (da) 2011-05-30
RU2003131687A (ru) 2005-02-27
CZ304489B6 (cs) 2014-05-28
EP1373207B1 (en) 2011-02-16
CZ20032583A3 (cs) 2004-01-14
JP2004534008A (ja) 2004-11-11
HUP0303639A3 (en) 2007-05-02
CN1238342C (zh) 2006-01-25
CN1501916A (zh) 2004-06-02
US6936625B2 (en) 2005-08-30
ATE498612T1 (de) 2011-03-15
DE60239193D1 (de) 2011-03-31
MXPA03008675A (es) 2003-12-12
WO2002079158A1 (en) 2002-10-10
ES2360787T3 (es) 2011-06-09
IL158082A (en) 2009-07-20
KR100452491B1 (ko) 2004-10-12
HU227919B1 (en) 2012-06-28
CA2441613A1 (en) 2002-10-10
KR20020076561A (ko) 2002-10-11
NZ528362A (en) 2005-04-29
EP1373207A1 (en) 2004-01-02

Similar Documents

Publication Publication Date Title
BR0208468A (pt) Camsilato de amlodipina e processo para sua preparação
BRPI0407734A (pt) derivados de adamantano, processo para sua preparação e composições farmacêuticas os contendo
BR0213242A (pt) Composto ou um seu sal ou solvato, composto e seus sais de adição de ácido fisiologicamente aceitáveis, composição farmacêutica, método de tratamento de um ou mais distúrbios, uso de um composto, e, processo de preparação de um composto
BRPI0408681A (pt) compostos, composições farmacêuticas, uso de um derivado da 1,2,3,4-tetraidroisoquinolina, método para tratar ou prevenir doenças, processo para a manufatura de composições farmacêuticas, e, uso de um ou mais compostos
BR9808953A (pt) Composto, processo para tratar um distúrbio mediado pela ciclooxigenase-2 em um paciente, e, composição farmacêutica
BR9908488A (pt) Composição farmacêutica de topiramato
BRPI0212455B8 (pt) composto derivado de fenetanolamina para o tratamento de doenças respiratórias, formulação farmacêutica, combinação, e, uso do mesmo
BR0108600A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, métodos para tratamento de uma doença mediada por quimiocina e para tratamento de uma doença inflamatória
BR0315296A (pt) Derivados do ciclohexanol espirocìclicos
BR9915727A (pt) ésteres derivados de compostos de fenil-ciclohexila substituìdos
BR0211601A (pt) Polimorfo estável de flibanserina, processo técnico para a preparação do mesmo e o uso do mesmo para a preparação de medicamentos
BR0214243A (pt) Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida
ES2093440T3 (es) Derivados en la serie de la vitamina d con modificaciones en la posicion 20, procedimiento para su preparacion, productos intermedios para este procedimiento, preparados farmaceuticos que contienen estos derivados asi como su utilizacion para la preparacion de medicamentos.
UY27548A1 (es) Sales de ácido succínico de 5,7,14-triazatetraciclo (10.3.1.02.11.04,9) exadeca-2 (11),3,5,7,9-pentaeno y composiciones farmacéuticas
BR0113590A (pt) 7-oxo-piridopirimidinas
BR0107899A (pt) Processo para produzir uma preparação de ingrediente ativo compreendendo ibuprofeno, preparação de ingrediente ativo, uso da mesma, preparação farmacêutica, uso da mesma, processo para produzir formas de dosagem sólidas, e, forma de dosagem sólida
AU1114492A (en) Nmda antagonists
BR0013313A (pt) Derivados substituìdos de pirrolidino-2,3,4- triona-3-oxina eficazes como antagonistas de receptores de nmda
BR9915436A (pt) Certas caprolactamas substituìdas, composições farmacêuticas contendo as mesmas e seu uso no tratamento de tumores
BR0016941A (pt) Derivados de aminometil-fenil-ciclohexanona
UY27372A1 (es) Derivados de bencimidazol 1-aril-2-n, s u o-sustituidos, su uso para la obtención de medicamentos y preparados farmacéuticos que contienen estos derivados
BR0109252A (pt) Composto, processo para produzir um composto, composição farmacêutica, e, uso de um composto ou de uma composição
BR9905904A (pt) Compostos espiro imidazolina, um processo para a sua preparação e composições farmacêuticas contendo os mesmos
BR0211734A (pt) Derivados do ácido 5,6,6a,11b-tetraidro- 7-oxa-5-aza- benzo [c] fluoreno-6-carboxìlico substituìdos como antagonistas do nmda
BR0017379A (pt) Composto polissacarìdeo, método para a obtenção do composto, uso do composto e preparação farmacêutica

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: HANMI HOLDINGS CO., LTD. (KR)

Free format text: TRANSFERIDO DE: HANMI PHARM. CO., LTD.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: HANMI SCIENCE CO., LTD. (KR)

B25G Requested change of headquarter approved

Owner name: HANMI SCIENCE CO., LTD. (KR)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/4422 (2006.01), C07D 211/84 (2006.01), C07

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/03/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2716 DE 24/01/2023 POR TER SIDO INDEVIDA.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 28/03/2022